Evidence map›Paper›PMID 35462410›Full record

ArticleThe oncologist2022

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.

Bassel Nazha, Tony Z Zhuang, Hiba I Dada, Leylah M Drusbosky, Jacqueline T Brown, Deepak Ravindranathan, Bradley C Carthon, Omer Kucuk, Jamie Goldman, Viraj A Master and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Adrenocortical stem cells in health and disease.Nature reviews. Endocrinology · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Bassel NazhaWinship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID 0000-0001-6385-1329
Tony Z ZhuangDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Hiba I DadaGuardant Health, Redwood City, CA, USA.
Leylah M DrusboskyGuardant Health, Redwood City, CA, USA.
Jacqueline T BrownWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Deepak RavindranathanWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Bradley C CarthonWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Omer KucukWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Jamie GoldmanWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Viraj A MasterWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Mehmet Asim BilenWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Emory University · USGuardant (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing of circulating cell-free tumor DNA (ctDNA) in patients with ACC, to characterize the genomic landscape of alterations, and to identify potential clinically actionable mutations.

methodsRetrospective analysis of genomic data from 120 patients with ACC who had ctDNA testing between 12/2016 and 10/2021 using Guardant360 (Guardant Health, CA) was performed. ctDNA NGS analysis interrogated single nucleotide variants, fusions, indels, and copy number amplifications of up to 83 genes. The frequency of genomic alterations, landscape of co-occurring mutations, and pathogenic/likely pathogenic alterations with potential targeted therapies was identified. The prevalence of alterations identified in ctDNA was compared to those detected in tissue using a publicly available database (cBioPortal).

resultsThe median age of this cohort was 53 years (range 21-81), and 56% of patients were female. Ninety-six patients (80%) had ≥1 somatic alteration detected. TP53 (52%), EGFR (23%), CTNNB1 (18%), MET (18%), and ATM (14%) were found to be the most frequently altered genes in ACC samples. Pathogenic and/or likely pathogenic mutations in therapeutically relevant genes were observed in 56 patients (47%) and included EGFR, BRAF, MET, CDKN2A, CDK4/6, and ATM. The most frequent co-occurring mutations were EGFR + MET (9%), MET + CDK4 (7%), EGFR + CDK4 (7%), and BRAF + MET (7%). The frequencies of mutations detected in ctDNA were similar to those detected in tissue.

conclusionsUtilizing blood-based NGS to characterize genomic alterations in advanced ACC is feasible in over 80% of patients. Almost half of the patients had actionable mutations with approved therapies in other cancers. This approach might inform the development of personalized treatment options or identify clinical trials available for this aggressive malignancy.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaCirculating Tumor DNAAdultAgedAged, 80 and overBiomarkers, TumorErbB ReceptorsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProto-Oncogene Proteins B-rafRetrospective StudiesBiomarkers, TumorCirculating Tumor DNAErbB ReceptorsProto-Oncogene Proteins B-rafadrenal canceradrenocortical carcinomacirculating tumor DNA (ctDNA)next-generation sequencingpersonalized medicine

Identifiers

PMID35462410
PMCPMC9177103
OpenAlexW4224867160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.